Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
4(9%)
Results Posted
12%(3 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_4
11
23%
Ph not_applicable
15
32%
Ph phase_1
3
6%
Ph phase_2
8
17%
Ph early_phase_1
3
6%
Ph phase_3
3
6%

Phase Distribution

6

Early Stage

8

Mid Stage

14

Late Stage

Phase Distribution43 total trials
Early Phase 1First-in-human
3(7.0%)
Phase 1Safety & dosage
3(7.0%)
Phase 2Efficacy & side effects
8(18.6%)
Phase 3Large-scale testing
3(7.0%)
Phase 4Post-market surveillance
11(25.6%)
N/ANon-phased studies
15(34.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.6%

25 of 31 finished

Non-Completion Rate

19.4%

6 ended early

Currently Active

4

trials recruiting

Total Trials

47

all time

Status Distribution
Active(6)
Completed(25)
Terminated(6)
Other(10)

Detailed Status

Completed25
unknown9
Withdrawn4
Recruiting3
Terminated2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
47
Active
4
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (7.0%)
Phase 13 (7.0%)
Phase 28 (18.6%)
Phase 33 (7.0%)
Phase 411 (25.6%)
N/A15 (34.9%)

Trials by Status

active_not_recruiting12%
completed2553%
terminated24%
recruiting36%
unknown919%
not_yet_recruiting24%
suspended12%
withdrawn49%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT05267886Phase 4

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Recruiting
NCT07000994Not Applicable

Dobutamine During Major Abdominal Surgery

Completed
NCT07406477Phase 2

The PROTECT-HIE Pilot Trial

Not Yet Recruiting
NCT06462313Not Applicable

Dobutamine for Management of Surgical Patients With Septic Shock

Completed
NCT04166331Phase 3

Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion

Completed
NCT03621618Not Applicable

Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.

Withdrawn
NCT07186062

Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function

Completed
NCT04020172Phase 1

Improving Tissue Oxygenation in Breast Reconstruction Surgery

Completed
NCT05350592Phase 2

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Active Not Recruiting
NCT05196815Not Applicable

Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI

Completed
NCT05953142Phase 2

Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.

Not Yet Recruiting
NCT05999487Not Applicable

Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital

Unknown
NCT05944146Not Applicable

Consistency of Carotid Doppler Blood Flow and Thermodilution Technique

Recruiting
NCT05797584Not Applicable

Right Ventricular Contractile Reserve in HF

Recruiting
NCT03846765Phase 4

Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).

Completed
NCT05241912Early Phase 1

Supernormal Oxygen Delivery for Patients With Severe Burns

Unknown
NCT04249258Early Phase 1

Dobutamine on the Cardiac Conduction System

Completed
NCT03207165Phase 4

Milrinone Versus Dobutamine in Critically Ill Patients

Completed
NCT02133105Phase 3

Levosimendan Versus Dobutamine for Renal Function in Heart Failure

Completed
NCT00624650Phase 2

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Completed

Drug Details

Intervention Type
DRUG
Total Trials
47